



Teleconference – March CEO Update

Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) invites interested parties to listen to the teleconference which was held on Thursday, 22 March 2018.

The audio only webcast is now available for on-demand viewing for six months (expiring 22 September 2018) via this link:

<http://edge.media-server.com/m/go/phosphagenics-ceo-update-0318>

Enquiries

Dr Ross Murdoch
Phosphagenics Limited
+61 3 9002 5000

About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM[®] (Tocopheryl Phosphate Mixture). TPM[®] is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing TPM[®] enhanced patches, gels and injectable products for the human health market and is also developing TPM[®] to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

Unit A8, 2A Westall Road, Clayton VIC 3168 Australia

Tel: +61 (0)3 9002 5000

www.phosphagenics.com Email: info@phosphagenics.com